UNTIL ALL SURVIVE.
We believe in a world where Cancer Outliers become the blueprint for curing everyone because miracles should happen to all.
Cure51 is co-founded with worldwide leading oncology centers
1
1
LEADING
PARTNERS
1+
1+
CENTERS
1
1
COUNTRIES
0k+
0k+
PATIENTS
OUR MISSION

WE IDENTIFY AND COLLECT UNIQUE DATA FROM THOUSANDS OF long-term cancer SURVIVORS.
Oncology players usually look at the biology of the 99% of the patients who die from the most lethal Cancers.
We are focusing on exceptional Cancer survivors from across all continents, to build a unique clinical and multi-omics database and contribute to Cancer eradication.
Cure51 focuses on extraordinary patients.
the Exception
that proves
the rule.
Our exceptional survivor community is a living proof that nature can beat Cancer.
OUR NETWORK
THE COLLECTIVE WILL SHAPE THE CURE
→ Building
1
1
Cohorts of patients
→ Analyzing
1
1
omics modalities
→ Collaborating with
1
1
BEST-IN-CLASS LABS
→ Bringing together
0
0
Nationalities
→ Building a team of
+6
+6
Talents
→ Speaking
1
1
Languages
OUR SCIENTIFIC LEADERS
Our Scientific Steering Committee
includes world-renowned oncologists
JOSEP TABERNERO, MD, PhD
Director Vall d’Hebron Institute of Oncology, Barcelona

FABRICE ANDRÉ, MD, PhD
President Elect ESMO Research Director Institut Gustave Roussy, Villejuif

OLIVIER ELEMENTO, PhD
Director of Englander Institute for Precision Medicine at Cornell University, NY

LOUIS DE MESTIER, MD
Principal Investigator Hopital Beaujon, AP-HP, Paris

PAN-CHYR YANG, MD, PhD
Principal Investigator National Taiwan University Hospital (NTUH)

NELSON DUSETTI, PhD
Research Director, INSERM | Pancreatic Cancer & Translational Oncology

SCOTT KOPETZ, MD
Head of Colorectal Cancer Moonshot programs MD Anderson, Houston

SOLANGE PETERS, MD, PhD
Head of Medical Oncology CHUV Lausanne

ULRICH KEILHOLZ, MD, PhD
LEAD SCLC, Director Charité Comprehensive Cancer Center Berlin
JEAN-YVES BLAY, MD, PhD
President UniCancer & Director Centre Léon Bérard, Lyon
























